Fournier's Gangrene Claims in South Carolina | Diabetes Medication Caused?
Text Us! (843) 755-4218

Fournier’s Gangrene Claims in South Carolina

Fournier’s Gangrene from SGLT2 inhibitor

If you or your loved one have developed Fournier’s gangrene after taking certain types of prescribed diabetic medications, you could be entitled to substantial compensation. A new class of diabetes drugs called SGLT2 inhibitors has been linked to this serious and potentially disfiguring or fatal disease. Our attorneys are currently investigating the potential claims of South Carolina patients who took medications such as Invokana, Jardiance, or Farxiga for diabetes at their doctors’ direction and subsequently developed severe infections of the perineum. Contact us for a free, no-obligation, confidential review of your claim.

Fournier's Gangrene | Did My Diabetes Medication Cause This Rare Disorder?

What is Fournier’s Gangrene?

Fournier’s gangrene is a rare necrotizing condition of the perineum and genitals. In this disease, flesh-eating bacteria attack the tissues of the perineal, perianal, and genital regions. The infections can rapidly progress into gangrene, causing severe injury and tissue death that may require multiple surgeries, including genital amputations. The National Organization for Rare Disorders reports that around 1,800 cases have been reported worldwide since the 1950s, affecting mostly men. While this disease is rare, a number of recent cases have been linked to SGLT2 inhibitors, and the new cases have impacted nearly as many women as men.

What is an SGLT2 Inhibitor?

A sodium-glucose cotransporter-2 inhibitor is a type of medication that helps the kidneys to remove excess sugar from the body of diabetics. The sugar is then removed from the body through the urine. This class of medications is commonly prescribed by doctors to diabetic adults in addition to dietary and lifestyle change recommendations to lower blood sugar. SGLT2 inhibitor drugs that may be linked to Fournier’s gangrene and that have been approved by the FDA include the following:

  • Invokana
  • Jardiance
  • Farxiga
  • Invokamet
  • Glyxambi
  • Qtern
  • Steglatro
  • Segluromet
  • Synjardy
  • Steglujan
  • Xigduo

If you are taking one of these medications and are experiencing the symptoms of Fournier’s gangrene, it is important for you to seek medical attention immediately to get treatment. If you are diagnosed with this disease, you should talk to one of our experienced complex litigation attorneys for a free evaluation of your claim.

SGLT2 manufacturers

The manufacturers of the SGLT2 inhibitors that may cause Fournier’s gangrene include the following:

  • AstraZeneca – Developed Xigduo, Xigduo XR, and Farxiga together with Bristol-Myers Squibb
  • Eli Lilly and Company – Developed Glyxambi and Jardiance in conjunction with Boehringer Ingelheim
  • Janssen Pharmaceutical – Subsidiary of Johnson & Johnson that is licensed to market Invokamet, Invokamet XR, and Invokana

All drug manufacturers, including the manufacturers of SGLT2 inhibitors, have a duty to test potentially harmful drugs and to warn physicians and patients about the harmful side effects that the drugs might cause. While only 12 cases have been identified in the past five years, those cases only include the ones that were reported to the FDA. It is possible that many more cases have occurred that have not been reported. The FDA reports that an estimated 1.7 million Americans are currently prescribed SGLT2 inhibitors to treat diabetic conditions.

Symptoms of Fournier’s Gangrene

A very serious infection of the genitals and genital region, Fournier’s gangrene can cause multiple symptoms. If you experience any of these symptoms, getting prompt medical attention is crucial so that you might be able to limit the progression of the disease. The infection can rapidly progress to gangrene, making early medical intervention vital. The symptoms include the following:

  • Tenderness and pain in the genitals and perineum
  • Redness of the genitals and perineum
  • Swelling in the genital region
  • Fever above 100.4 degrees Farhenheit
  • Anemia
  • Dehydration
  • A crackling sound when the area is rubbed
  • Unpleasant smell from the area caused by necrotized flesh
  • Nausea, malaise, and flu-like symptoms
  • Oozing, blistery sores

The symptoms of the infection can worsen very quickly as the necrotizing bacteria are aggressive. People who experience any of these symptoms should immediately go to their doctors’ offices for a medical evaluation.

The FDA and SGLT2 Inhibitors

On Aug. 29, 2018, the FDA issued a drug safety communication about the link between SGLT2 inhibitors and Fournier’s gangrene. The SGLT2 inhibitors were initially approved by the FDA in 2013. The drug safety communication noted the link between these drugs and necrotizing fasciitis of the genitals and perineum and made recommendations for both patients and doctors.

In a safety announcement that was also issued on Aug. 29, the FDA stated that 12 cases of Fournier’s gangrene were identified in patients who were prescribed SGLT2 inhibitors between 2013 and 2018. Of these people, seven were men and five were women. All of the patients required surgeries to remove gangrenous tissue and were hospitalized. Some of the patients had to undergo multiple, disfiguring surgeries, and one of the patients died. The patients developed Fournier’s gangrene within a few months of being prescribed SGLT2 inhibitors for type 2 diabetes. By contrast, the FDA notes that over a period of 30 years, just one case of Fournier’s gangrene was identified among men who were prescribed other types of diabetic medications.

Fournier’s Gangrene Litigation

Because SGLT2 inhibitors are newer medications and the link between the drugs and Fournier’s gangrene has only recently become known, there have not been any settlements or jury trials to date. However, lawsuits have been filed, including a potential multidistrict litigation that was filed in federal court in New Jersey in Sept. 2018 as MDL 2750. The lawsuits that have been filed are in their initial stages.

What Compensation Might Be Recoverable?

The compensation that you might be able to recover for developing SGLT2 inhibitor-linked Fournier’s gangrene will depend on the extent of your injury and a combination of your economic and noneconomic losses. Some of the types of compensation to which you might be entitled include the following:

  • Disfigurement
  • Physical pain and suffering
  • Mental anguish
  • Loss of consortium for spouses
  • Past and future medical costs
  • Income losses
  • Reductions in your future ability to earn an income
  • Lost inheritance rights if your loved one died
  • Lost income of your loved one who died
  • Funeral and burial costs

Economic damages are known as special damages and are types of compensatory damages for your pecuniary losses. Noneconomic damages are losses that are more intangible and are types of compensatory damages that are known as general damages.

In addition to these types of compensatory damages, it may also be possible to recover punitive damages. These are damages that are meant to punish defendants for particularly outrageous or egregious conduct to deter them from engaging in similar actions in the future.

The Importance of Getting Legal Help

If you have been diagnosed with Fournier’s gangrene or have lost a loved one to this disease after being prescribed one of the SGLT2 inhibitors, you may be entitled to substantial compensation for the harm that you have suffered. Getting help from a local legal team is important. Our experienced South Carolina attorneys can analyze the facts and circumstances of your case an provide you with an honest assessment of your potential claim. Contact our law firm today to schedule your confidential claim evaluation.

Free Case Evaluation

The Carolina Justice Report Podcast

Categories

Top 40 under 40 Top 100 trial lawyers National Trial Lawyers Top 100 Martindale AV Certificate Trial Lawyers Top 100

South Carolina Association of Criminal Defense Lawyers South Carolina Association for Justice 10 Best 2014